Manisha Miller, Lynn Schoenfield, Mohamed Abdel-Rahman, Colleen M Cebulla
{"title":"Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma.","authors":"Manisha Miller, Lynn Schoenfield, Mohamed Abdel-Rahman, Colleen M Cebulla","doi":"10.1159/000514650","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite a higher incidence and worse prognosis of uveal melanoma (UM) in men, there have been many case reports of pregnant patients with aggressive UM. This has led researchers to explore the influence of sex hormones and pregnancy on the development and progression of UM and hormones as potential therapeutic targets.</p><p><strong>Summary: </strong>A systematic literature review was conducted. More work is needed to elucidate the basis of sex differences in UM incidence and survival. The evaluation of germline <i>BAP1</i> mutation would be beneficial in patients with UM presenting at a young age. Importantly, multiple studies reported no significant difference between the 5-year survival and 5-year metastasis-free survival rates between nonpregnant women with UM and pregnant women with UM. Multiple case-control studies disagree on how parity affects risk of UM. However, most studies agree that oral contraceptives and hormone replacement therapy have no effect on the incidence of UM. Current treatment strategies for pregnant patients with UM are discussed. Looking forward, this review reports recent research on targeted receptor-based chemotherapy, which is based on evidence of estrogen receptor (ER), estrogen-related receptor alpha (ERRα), and luteinizing hormone-releasing hormone (LHRH) receptor expression in UM.</p><p><strong>Key messages: </strong>Based on review of the literature, UM is not a contraindication to oral contraceptives, hormone replacement therapy, or pregnancy. Globe-sparing radiation can be used as a treatment option for pregnant patients. Due to the presence of ER on a subset of unselected UM, its potential for adjunctive targeted therapy with agents like tamoxifen should be explored. Lessons from cutaneous melanoma regarding tissue ratios of estrogen receptors (ERα:ERβ) should be applied to assess their therapeutic predictive value. In addition, ERRα-targeted therapeutics and LHRH analogs are worthy of further exploration in UM.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"7 4","pages":"239-250"},"PeriodicalIF":0.9000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443925/pdf/oop-0007-0239.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000514650","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite a higher incidence and worse prognosis of uveal melanoma (UM) in men, there have been many case reports of pregnant patients with aggressive UM. This has led researchers to explore the influence of sex hormones and pregnancy on the development and progression of UM and hormones as potential therapeutic targets.
Summary: A systematic literature review was conducted. More work is needed to elucidate the basis of sex differences in UM incidence and survival. The evaluation of germline BAP1 mutation would be beneficial in patients with UM presenting at a young age. Importantly, multiple studies reported no significant difference between the 5-year survival and 5-year metastasis-free survival rates between nonpregnant women with UM and pregnant women with UM. Multiple case-control studies disagree on how parity affects risk of UM. However, most studies agree that oral contraceptives and hormone replacement therapy have no effect on the incidence of UM. Current treatment strategies for pregnant patients with UM are discussed. Looking forward, this review reports recent research on targeted receptor-based chemotherapy, which is based on evidence of estrogen receptor (ER), estrogen-related receptor alpha (ERRα), and luteinizing hormone-releasing hormone (LHRH) receptor expression in UM.
Key messages: Based on review of the literature, UM is not a contraindication to oral contraceptives, hormone replacement therapy, or pregnancy. Globe-sparing radiation can be used as a treatment option for pregnant patients. Due to the presence of ER on a subset of unselected UM, its potential for adjunctive targeted therapy with agents like tamoxifen should be explored. Lessons from cutaneous melanoma regarding tissue ratios of estrogen receptors (ERα:ERβ) should be applied to assess their therapeutic predictive value. In addition, ERRα-targeted therapeutics and LHRH analogs are worthy of further exploration in UM.
背景:尽管葡萄膜黑色素瘤(UM)在男性中发病率较高且预后较差,但仍有许多关于妊娠患者罹患侵袭性 UM 的病例报告。这促使研究人员探索性激素和妊娠对葡萄膜黑色素瘤发病和进展的影响,以及作为潜在治疗靶点的激素。需要做更多的工作来阐明 UM 发病率和存活率的性别差异基础。评估种系BAP1基因突变对年轻UM患者有益。重要的是,多项研究报告称,非妊娠女性 UM 患者与妊娠女性 UM 患者的 5 年生存率和 5 年无转移生存率之间没有显著差异。多项病例对照研究对奇数妊娠如何影响罹患子宫内膜异位症的风险存在分歧。不过,大多数研究一致认为,口服避孕药和激素替代疗法对 UM 的发病率没有影响。本综述还讨论了目前针对妊娠合并子宫内膜异位症患者的治疗策略。展望未来,本综述报告了基于受体的靶向化疗的最新研究,这种化疗是基于雌激素受体(ER)、雌激素相关受体α(ERRα)和促黄体生成素释放激素(LHRH)受体在 UM 中表达的证据:根据文献综述,UM 并非口服避孕药、激素替代疗法或妊娠的禁忌症。妊娠患者可选择保甲放射治疗。由于ER存在于部分未经选择的UM上,因此应探索其与他莫昔芬等药物进行辅助靶向治疗的潜力。应借鉴皮肤黑色素瘤组织雌激素受体(ERα:ERβ)比率的经验,评估其治疗预测价值。此外,ERRα靶向疗法和LHRH类似物也值得在UM中进一步探索。